This Week in Crypto Law (Mar. 29, 2026) – Law and Ledger Bitcoin News
This Week in Crypto Law The opinion editorial below was written by Alex Forehand and Michael Handelsman for Kelman.Law. The […]
Is ABIVAX (ENXTPA:ABVX) Pricing Reflect Its Sharp Multi‑Year Share Price Surge
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply
Belgian Crypto Startup Keyrock Sees Valuation Top $1 Billion
Keyrock, a crypto-focused investment group based in Belgium, is now a $1.1 billion company. The company announced that valuation last
Is It Time To Revisit GitLab (GTLB) After Recent Share Price Swings?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
The Crypto News That Changed How Smart Money Thinks About
The right investment at the right time changes everything, and the crypto news cycle just delivered the proof in two
Best Crypto to Buy Now as Coinbase Battles CFTC While Pepeto Gains
The best crypto to buy now is the project that arms you with tools for every step of the trading
How Japan’s Crypto Travel Rule Amendment Gives FSA New Transaction Surveillance Powers – Regulation Bitcoin News
Key Takeaways: On April 25, 2025, Japan FSA added 30 jurisdictions to its crypto travel rule network. Japan’s 58-market scope
Can Robinhood Buy SpaceX IPO Shares? Which Investment Banks Are Participating in Underwriting? How Can Retail Investors in Asia and Europe Invest in SpaceX?
TradingKey – According to Reuters, citing sources familiar with the matter, Elon Musk’s SpaceX is expected to go public later
Crypto attorney says Drift incident may qualify as ‘civil negligence’ — TradingView News
The hack of the Solana-based decentralized finance (DeFi) platform Drift Protocol could have been prevented if standard operational security procedures
Will Priority FDA Review of Zilganersen and Tryngolza Pricing Shift Ionis Pharmaceuticals’ (IONS) Narrative
Ionis Pharmaceuticals recently announced that the FDA accepted for Priority Review its New Drug Application for zilganersen, an RNA-targeted therapy